This drug, approved for the clinical treatment of patients with multiple myeloma and bone metastases [253], also inhibits BC growth, migration and invasion by targeting various ECM proteins, including integrins ανβ3, ανβ5, and α5β1, and Sdc-1, and by suppressing the expression of MMP-2 and MMP-9 [254]. The gene discussed is SDC1; the disease is plasma cell myeloma.